PERmixon® in LUTS Evaluation Study (PERLES)

PHASE4CompletedINTERVENTIONAL
Enrollment

833

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
DRUG

Permixon® 160 mg

Oral administration - 160 mg twice daily.

DRUG

Tamsulosine LP

Oral administration - 0.4 mg daily.

DRUG

Placebo matching Permixon® 160 mg

Oral administration - twice daily.

DRUG

Placebo matching Tamsulosine LP

Oral administration - daily.

Trial Locations (58)

Unknown

Benešov

Litoměřice

Pilsen

Prague

Roudnice nad Labem

Sternberk

Ústí nad Labem

Angers

Créteil

Limoges

Lyon

Marseille

Montreuil-Juigné

Nice

Nieul-sur-Mer

Paris

Saint-Orens-de-Gameville

Seysses

Tiercé

Berlin

Hagenow

Halle

Hamburg

Herzogenaurach

Hettstedt

Leipzig

Markkleeberg

Michelstadt

Mülheim

Nuremberg

Regensburg

Bari

Catanzaro

Foggia

Messina

Milan

Napoli

Novara

Orbassano

Padua

Palermo

Pesaro

Pietra Ligure

Prato

Roma

Udine

Barcelona

Coslada

El Palmar Murcia

Figueres

Getafe

Madrid

Parla

Sabadell

Salamanca

San Sebastián de los Reyes

Seville

Utrera de la Encomienda

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY

NCT02121613 - PERmixon® in LUTS Evaluation Study (PERLES) | Biotech Hunter | Biotech Hunter